Antibody\mRNA
vaccine
YB1-CD47
YB1-mRNA
YB1-CD47
YB1-mRNA
-
30 minutesGuidance period
Looking for the location of the tumor -
-
Within 24 hoursThe stage of tumor targeging
Starting a large number of replication -
-
24 hoursDrug release period
The period of drug release and causing oncolysis
-
Technical Characteristics of YB1- YB1 could extend drug effect to enhance effectiveness
- Tumor targeting could achieve special survival and have high safety.
- Defining mechanism of antineoplastic.
- It can release drugs to significantly inhibit tumor growth and metastasis
-
Application of YB1 in pet primary cancer treatment- Sarcoma
- Melanoma
- Mammary cancer
- Mastocytoma
-
2011
For the first time, the high efficiency programming technology of Salmonella Lambda-RED was realized, and the foundation of synthetic biology transformation of Salmonella was established.
-
2012
Apply for YB1 related invention patents, including PCT, the United States, the European Union, China, etc;
The first paper of YB1 was published in the subsidiary of the famous academic journal Nature. -
2013
YB1 related patents of the United States, EU and China are authorized; -
2016
It was the first time that the pet dog named Noopy with malignant sarcoma was recovered by using YB1. -
2020
Completed the pet cancer YB1 clinical study, involving over 100 pet dogs with cancer. The Pet dog Noopy achieved 4-year cancer-free survival; -
2021
HKND YB1 PHARMACEUTICAL LIMITED has established a strategic partnership with HKU of the University of Hong Kong and obtained the exclusive license and commercial exploitation right of all YB1 patents; -
2021
On May 5, 2021, Inventor Dr. Yu Bin from the University of Hong Kong and his team published the title "IFN" in the international well-known journal Nature Communications- γ- The research paper of dependent NK cell activation is essential to metastasis suppression by engineered Salmonella, elaborates the principle of YB1, a tumor solubilizing bacteria invented by Dr. Yu Bin team, and provides an important research direction for cancer immunotherapy. The influence factors of the paper are more than 20;
The world's first oncolytic bacterial carrier
-
It is safe and effective, and can self replicate in a large number of tumors -
Strong drug delivery capability -
High quality compatibility -
Combined with liquid biopsy of urine tumor, it can be commercialized quickly
In 2021, HKND YB1 PHARMACEUTICAL LIMITED has established a strategic partnership with HKU of the University of Hong Kong, and obtained all patents and commercial exploitation right of YB1.
Founded on March 16, 1910, the University of Hong Kong (HKU), formerly known as the Hong Kong Academy of Western medicine, is the oldest institution of higher education in Hong Kong, an international public research university, and an "Ivy League" University in Asia.
As an important strategic shareholder of HKND YB1 PHARMACEUTICAL LIMITED, HKU has the international top scientific research strength and level as well as strong academic research atmosphere and environment. It is also the initial soil for cultivating and inventing the core technology of YB1. HKU provides a strong and reliable help for the technological development of YB1 and the future development of HKND YB1 PHARMACEUTICAL LIMITED. It is an important shareholder and partner to make progress together.
At present, HKU has five national key laboratories, five joint laboratories with the Chinese Academy of Sciences, and more than 90 scientific research institutions affiliated to HKU. Its research productivity and influence have attracted worldwide attention.
From 2019 to 2020, the total number of collaborative research, contract research, consultancy services cooperated with HKU was up to 2097; the number of valid patents and technology grants was 133. The number of valid patents and patent applications was 2093.
